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Background

Results

Bladder cancer represents the 6th most common for men and is classified
into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder
cancer (NMIBC).1 NMIBC (T1, Ta, Tis), accounting for approximately 75% of new
bladder cancer diagnoses, is limited to the mucosa, submucosa, and lamina
propria.2 Studies have approximated the rate of recurrence in NMIBC between
50 - 70%, which sometimes progresses to muscle invasive disease.3
Management of NMIBC ranges from surveillance, intravesical chemotherapy to
radical cystectomy (RC) and is dependent upon the TNM staging and grading of
the tumor.4 Clinically, staging is determined via imaging, physical exam, and
histology on transurethral resection of bladder tumor (TURBT), while pathologic
grading is determined via radical cystectomy and pelvic lymph node dissection
(PLND).5
PLND has been shown to have a therapeutic benefit in localized bladder
cancer when done in conjunction with RC, in addition to diagnostic and
therapeutic elements.6 While the relationship between PLND and MIBC has been
studied extensively, the role of lymph node (LN) dissection during RC for NMIBC
remains unclear, with few studies and conflicting results.6,7,8 Furthermore,
although lymph node metastasis has been found to occur in up to 16.2% of
NMIBC patients, its reported that nearly half have insufficient PLND during RC
and 16.6% have no PLND done at all.9,7 The aim of this data analysis is to
determine the predictive factors and outcomes for LN positive patients
undergoing PLND with RC in NMIBC.

Discussion
• While PLND for MIBC has shown accurate nodal staging, decreased local
recurrence, and higher survival rates, the role of PLND in NMIBC is typically
more diagnostic; yet given the frequency of LN metastasis in NMIBC, this role
should be reconsidered.10,11,8
• 29% of patients diagnosed with MIBC or NMIBC have pathologically node
confirmed metastasis.12 Staging for NMIBC is important for predicting morbidity
and mortality, and thus sufficient PLND is essential for prognosis.
• Our findings of statistically significantly higher rates of rectal injury, wound
disruption, and return to the operating room in LN positive patients may be
explained by the increase in operating time needed to complete a more
thorough PLND and the increased risks of complications that arise such as
lymphocele formation, thromboembolic events and direct injury to surrounding
structures.13
• There remains disagreement as to the ideal anatomical template and number
of nodes needed in PLND.14 Some surgeons take only internal and external
iliac LNs, while others dissect all nodes between the aortic bifurcation, common
iliac vessels, genitofemoral nerves, circumflex iliac veins, and internal iliac
vessels, and sometimes even beyond.15-19
• In MIBC, >9 LNs were required to increase likelihood of accurate staging and
improve patient outcomes.20 Our findings suggest that in NMIBC, at least 16
LNs should be sampled.
• Even if templates are followed precisely, the potential of unidentified LN
outsides the defined region exists.21-23 Ultimately, consistency in dissection
technique is likely more important than total LN count in achieving improved
outcomes.17

Methods
Our data source was the National Surgical Quality Improvement Program
(NSQIP), a HIPAA compliant database which consists of de-identified patient data
from 706 participating hospital institutions including 273 variables on 1,076,441
cases in 2019 and variables on 902,968 cases in 2020 based on Current
Procedural Terminology (CPT) code.
Records identified from 2019-20
NSQIP Database
(n = 1,979,409)

Non-radical cystectomy patients
excluded
(n = 1,973,306)

Radical cystectomy patients
included
(n = 6,103)

Patients with T1, Ta, Tis or no data
on post-operative diagnosis
excluded
(n = 4,858)

NMIBC patients with LN evaluation
post-RC included
(n = 1,245)

Patients with no data on postoperative LN evaluation or
metastasis to region outside the
pelvis excluded
(n = 73)

LN positive (N1, N2, N3)
(n = 53)

LN negative (N0, Nx)
(n = 1,119)

LN positive patients were significantly more likely to have undergone
chemotherapy within 90 days of surgery (58.55% vs. 31.2%, p < 0.01). LN
positive patients were more likely to undergo rectal injury (1.9% vs. 0.8%, p =
0.02), return to the operating room (11.3% vs. 3.9%, p < 0.01), and experience
wound disruption (5.7% vs. 1.8%, p = 0.04). Other postoperative outcomes were
not statistically significant. ROC analysis demonstrates that 50% of lymph node
diagnoses were made with a PLND of at least 16 LNs.

Conclusion
Recent research demonstrates survival benefit in LN dissection in
patients with NMIBC, particularly for patients with cTis or T1 staging. Nearly
half of NMIBC patients undergoing RC do not receive an adequate PLND,
despite an association with increased overall survival. The present study
investigates predictive factors and outcomes for LN positive patients with
NMIBC. Further research is needed to advance our understanding of
PLND’s role in the management of NMIBC.
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